CVRx, Inc.

CVRx develops and commercializes implantable neuromodulation devices designed to treat cardiovascular diseases by modulating the autonomic nervous system. The company's primary product is Barostim, an implantable device that delivers electrical pulses to baroreceptors in the carotid artery wall. This therapy, known as baroreflex activation therapy, works by enhancing signaling between the cardiovascular and autonomic nervous systems to address conditions associated with decreased baroreceptor function.

The company operates as a commercial-stage medical device manufacturer with a direct sales model supplemented by sales agents and independent distributors. CVRx generates revenue primarily through device sales, with geographic presence in the United States, Germany, and select international markets. The organization maintains a focused operational scale with 223 full-time employees and maintains manufacturing and commercialization capabilities from its Minneapolis headquarters.